These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 26142357)

  • 21. Role of centralized review processes for making reimbursement decisions on new health technologies in Europe.
    Stafinski T; Menon D; Davis C; McCabe C
    Clinicoecon Outcomes Res; 2011; 3():117-86. PubMed ID: 22046102
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A review of international coverage and pricing strategies for personalized medicine and orphan drugs.
    Degtiar I
    Health Policy; 2017 Dec; 121(12):1240-1248. PubMed ID: 29033060
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dealing with Uncertainty and Accounting for Social Value Judgments in Assessments of Orphan Drugs: Evidence from Four European Countries.
    Nicod E; Berg Brigham K; Durand-Zaleski I; Kanavos P
    Value Health; 2017; 20(7):919-926. PubMed ID: 28712621
    [TBL] [Abstract][Full Text] [Related]  

  • 25. What is driving HTA decision-making? Evidence from cancer drug reimbursement decisions from 6 European countries.
    Maynou L; Cairns J
    Health Policy; 2019 Feb; 123(2):130-139. PubMed ID: 30477736
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Published and unpublished evidence in coverage decision-making for pharmaceuticals in Europe: existing approaches and way forward.
    Panteli D; Nolting A; Eckhardt H; Kulig M; Busse R
    Health Res Policy Syst; 2016 Jan; 14():6. PubMed ID: 26813738
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The role of economic evidence in Canadian oncology reimbursement decision-making: to lambda and beyond.
    Rocchi A; Menon D; Verma S; Miller E
    Value Health; 2008; 11(4):771-83. PubMed ID: 18179658
    [TBL] [Abstract][Full Text] [Related]  

  • 28. From market access to patient access: overview of evidence-based approaches for the reimbursement and pricing of pharmaceuticals in 36 European countries.
    Panteli D; Eckhardt H; Nolting A; Busse R; Kulig M
    Health Res Policy Syst; 2015 Sep; 13():39. PubMed ID: 26407728
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Characteristics of drugs for ultra-rare diseases versus drugs for other rare diseases in HTA submissions made to the CADTH CDR.
    Richter T; Janoudi G; Amegatse W; Nester-Parr S
    Orphanet J Rare Dis; 2018 Feb; 13(1):15. PubMed ID: 29386040
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The 2018 decision to establish an Advisory Council on adding pharmaceuticals to universal health coverage in Canada.
    Grignon M; Longo CJ; Marchildon GP; Officer S
    Health Policy; 2020 Jan; 124(1):7-11. PubMed ID: 31761273
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Systematic review on the evaluation criteria of orphan medicines in Central and Eastern European countries.
    Zelei T; Molnár MJ; Szegedi M; Kaló Z
    Orphanet J Rare Dis; 2016 Jun; 11(1):72. PubMed ID: 27259284
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Drug Policy in Greece.
    Yfantopoulos JN; Chantzaras A
    Value Health Reg Issues; 2018 Sep; 16():66-73. PubMed ID: 30195093
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Stakeholder involvement in expensive drug recommendation decisions: an international perspective.
    Rosenberg-Yunger ZR; Thorsteinsdóttir H; Daar AS; Martin DK
    Health Policy; 2012 May; 105(2-3):226-35. PubMed ID: 22226141
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Association between pacifier use and breast-feeding, sudden infant death syndrome, infection and dental malocclusion.
    Callaghan A; Kendall G; Lock C; Mahony A; Payne J; Verrier L
    JBI Libr Syst Rev; 2005; 3(6):1-33. PubMed ID: 27819973
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Drug reimbursement recommendations by the National Institute for Health and Clinical Excellence: have they impacted the National Health Service budget?
    Mauskopf J; Chirila C; Birt J; Boye KS; Bowman L
    Health Policy; 2013 Apr; 110(1):49-59. PubMed ID: 23434292
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Drug policy: making effective drugs available without bankrupting the healthcare system.
    Laupacis A; Anderson G; O'Brien B
    Healthc Pap; 2002; 3(1):12-30. PubMed ID: 12811107
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost-related prescription nonadherence in the United States and Canada: a system-level comparison using the 2007 International Health Policy Survey in Seven Countries.
    Kennedy J; Morgan S
    Clin Ther; 2009 Jan; 31(1):213-9. PubMed ID: 19243719
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Application of a policy framework for the public funding of drugs for rare diseases.
    Winquist E; Coyle D; Clarke JT; Evans GA; Seager C; Chan W; Martin J
    J Gen Intern Med; 2014 Aug; 29 Suppl 3(Suppl 3):S774-9. PubMed ID: 25029973
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Identifying and Revealing the Importance of Decision-Making Criteria for Health Technology Assessment: A Retrospective Analysis of Reimbursement Recommendations in Ireland.
    Schmitz S; McCullagh L; Adams R; Barry M; Walsh C
    Pharmacoeconomics; 2016 Sep; 34(9):925-37. PubMed ID: 27034245
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.